On December 30, 2020 Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, reported that the company was officially included into the Shenzhen-Hong Kong Stock Connect program (the "Hong Kong Stock Connect") (Press release, Ascentage Pharma, DEC 30, 2020, View Source [SID1234573343]). This was officially announced by the Shenzhen Stock Exchange ("SZSE") on December 25, 2020, which has been effective since December 28, 2020. This inclusion is the very first arrangement for the eligible pre-revenue biotech companies listed under Chapter 18A of Hong Kong’s Main Board Listing Rules, and complied with the conditions for the inclusion in the Hong Kong Stock Connect.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Hong Kong Stock Connect is a collaboration program between the Hong Kong, Shanghai and Shenzhen Stock Exchanges. Stock Connect allows international and China Mainland investors to trade securities in each other’s markets through the trading and clearing platforms of their home exchange. In this adjustment, a total of six eligible pre-revenue biotech companies will be the first included in the Hong Kong Stock Connect. The expansion of the eligible stocks of Hong Kong Stock Connect, will further optimize the interconnected, intercommunicated, and mutual development of the capital markets between Mainland China and Hong Kong.
As the first biotech stock specializing in small molecular innovative drugs, Ascentage Pharma has made significant progress in clinical development, external partnership, and patent distribution during the recent one year since its listing, and achieved a number of global collaborations, which is transforming the company from an R&D enterprise for self-innovative new drug to an R&D and manufacturing enterprise. In 2020, Ascentage Pharma made its first New Drug Application (NDA) and was granted priority review by China National Medical Products Administration (NMPA), achieving a significant milestone. During the past six months, the company has kept ahead in the industry, four new drugs have been granted eight Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA). In August, Ascentage Pharma was included in the Hang Seng Composite Index, the Hang Seng Hong Kong-Listed Biotech Index and the Hang Seng Healthcare Index, which have become effective in September 2020. Only over a year since the listing, Ascentage Pharma was included in the Hang Seng Index as well as the Hong Kong Stock Connect, fully demonstrating that its value for investment and the future prospect are highly recognized in the capital market.
"As one of the first batch of the arranged Chapter 18A companies according to the new regulation, the inclusion of the company is a significant milestone and fully reflects the recognition and confidence in the company’s business and development prospects from the capital market, and will facilitate further expansion of our investor base and enhance the liquidity of our stocks," said Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma. "In the future, we will adhere to the innovation strategy and continue strengthening the R&D, and maintaining our leading position in the industry in order to accelerate the global clinical development of our pipelines, We will commit to Ascentage Pharma’s mission of ‘addressing the unmet clinical needs in China and around the world’, benefitting worldwide patients and return to our public shareholders and investors."